Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis.

[1]  G. Pontone,et al.  Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. , 2020, JACC. Cardiovascular imaging.

[2]  M. Emdin,et al.  Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. , 2019, International journal of cardiology.

[3]  A. Manolis,et al.  Cardiac amyloidosis: An underdiagnosed/underappreciated disease. , 2019, European journal of internal medicine.

[4]  M. Maurer,et al.  Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.

[5]  Kathleen W. Zhang,et al.  Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis , 2019, JACC. Basic to translational science.

[6]  M. Emdin,et al.  Treatment of cardiac transthyretin amyloidosis: an update. , 2019, European heart journal.

[7]  A. González-Duarte.  Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis) , 2019, Clinical Autonomic Research.

[8]  G. Mancia,et al.  Sympathetic and baroreflex alterations in congestive heart failure with preserved, midrange and reduced ejection fraction , 2019, Journal of hypertension.

[9]  M. Mateos,et al.  Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients. , 2018, European journal of internal medicine.

[10]  M. Emdin,et al.  Therapies for cardiac light chain amyloidosis: An update. , 2018, International journal of cardiology.

[11]  S. Georgin-lavialle,et al.  Minor salivary gland biopsy is more effective than normal appearing skin biopsy for amyloid detection in systemic amyloidosis: A prospective monocentric study. , 2018, European journal of internal medicine.

[12]  P. Milani,et al.  Management of the elderly patient with AL amyloidosis. , 2018, European journal of internal medicine.

[13]  D. Goldstein,et al.  Cardiac Dysautonomia and Survival in Hereditary Transthyretin Amyloidosis. , 2016, JACC. Cardiovascular imaging.

[14]  R. Falk,et al.  AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. , 2016, Journal of the American College of Cardiology.

[15]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[16]  S. Park,et al.  Propensity Score Matching: A Conceptual Review for Radiology Researchers , 2015, Korean journal of radiology.

[17]  W. Verloop,et al.  A Systematic Review Concerning the Relation between the Sympathetic Nervous System and Heart Failure with Preserved Left Ventricular Ejection Fraction , 2015, PloS one.

[18]  Giuseppe Ambrosio,et al.  New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. , 2014, European heart journal.

[19]  Lluís Mont,et al.  2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). , 2013, European heart journal.

[20]  L. A. Bonet,et al.  ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2012, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[21]  C. Delcayre,et al.  Molecular mechanisms of myocardial remodeling. The role of aldosterone. , 2002, Journal of molecular and cellular cardiology.

[22]  W. Hsueh,et al.  Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. , 2000, Circulation.

[23]  M. Packer,et al.  Evolution of the neurohormonal hypothesis to explain the progression of chronic heart failure. , 1995, European heart journal.

[24]  J. Cohn.  Structural basis for heart failure. Ventricular remodeling and its pharmacological inhibition. , 1995, Circulation.

[25]  J. Floras.  Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. , 1993, Journal of the American College of Cardiology.

[26]  M. Packer.  The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. , 1992, Journal of the American College of Cardiology.

[27]  J. Cohn,et al.  Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. , 1984, The New England journal of medicine.

[28]  D. Shephard.  The 1975 Declaration of Helsinki and consent. , 1976, Canadian Medical Association journal.

[29]  P. Ponikowski,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016 .